Evommune (EVMN) Prepaid Assets (2024 - 2026)

Evommune (EVMN) posted quarterly Prepaid Assets of $4.4 million for Q1 2026, up 2.64% quarter-over-quarter from $4.3 million in Q4 2025.

Evommune (EVMN) Prepaid Assets (2024 - 2026) Analysis & Trends

Evommune (EVMN) has reported Prepaid Assets for 3 consecutive years, with $4.4 million the latest figure, recorded in Q1 2026.

In Q1 2026, Prepaid Assets changed N/A year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $4.4 million (changed N/A YoY), while the FY2025 annual figure was $4.3 million, up 119.61% from the prior year.
Prepaid Assets improved to $4.4 million in Q1 2026 per EVMN's latest filing, from $4.3 million in the prior quarter.
Across five years, Prepaid Assets topped out at $5.9 million in Q3 2025 and bottomed at $1.9 million in Q4 2024.
Historically, Prepaid Assets has averaged $4.1 million across 3 years, with a median of $4.3 million in 2025.
On a YoY basis, Prepaid Assets climbed as much as 119.61% in 2025 and fell as far as 119.61% in 2025.
Evommune's Prepaid Assets stood at $1.9 million in 2024, then surged by 119.61% to $4.3 million in 2025, then climbed by 2.64% to $4.4 million in 2026.
Business Quant data shows EVMN's Prepaid Assets at $4.4 million in Q1 2026, $4.3 million in Q4 2025, and $5.9 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Evommune	531.53 Mn	330.73 Mn	-

Download Data